Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMB-402
- Development stage
- Unknown
- Lead developer
- IM Biologics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IMB-402 is a multivalent T-cell engager (TCE) being developed by IMBiologics for the treatment of cancer, with a primary focus on glioblastoma. It is constructed using the proprietary ePENDY platform, which enables the creation of multivalent antibodies designed to function as dendritic cell mimetics. IMB-402 features a unique "1+10" molecular architecture, comprising one domain that recruits CD8+ T cells and ten domains that target undisclosed cancer-specific antigens. This high-avidity design is intended to enhance tumor targeting and immune activation, potentially overcoming the limitations of traditional IgG-based therapies. The platform is also described as being capable of activating both NK cells and T cells. As of early 2024, IMB-402 is in the discovery and screening stages of development.
- Other names
- STAM
02
Targets
CD8A (CD8 alpha/beta Coreceptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on IMB-402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMB-402.